Search Results 1151-1160 of 18735 for Relapse

  1. Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas - Mayo Clinic

    Other malignancy unless disease-free for ≥ 2 years and not expected to relapse or require treatment during study participation. Active systemic infection ...

  2. Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF - Mayo Clinic

    MF patients must have received prior JAK2 inhibitor therapy, and been found to be intolerant, or refractory/relapsed from prior JAK2 inhibitor therapy, based on ...

  3. Clinical trials - Oncology (Medical)

    This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT ( ...

  4. Clinical trials - Oncology (Medical)

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies ... relapse, and subsequent therapy. A Study of Nab-Paclitaxel as ...

  5. Cutaneous B-cell lymphoma - Diagnosis and treatment - Mayo Clinic

    It is sometimes combined with chemotherapy. Immunotherapy also may be used on relapsed and refractory cutaneous B-cell lymphoma. Monitoring after treatment.

  6. Clinical trials - Oncology (Medical)

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies ... relapse, and subsequent therapy. A Study of Nab-Paclitaxel as ...

  7. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens - Mayo Clinic

    For Daratumumab + lenalidomide + dexamethasone (D-Rd) regimen: relapsed or refractory disease. Eastern Cooperative Oncology Group (ECOG) Performance Status ...

  8. Clinical trials - Oncology (Medical)

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies ... relapse, and subsequent therapy. Effect of Agent Orange ...

  9. Clinical trials - Oncology (Medical)

    CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/​Refractory B Cell Malignancies ... relapse, and subsequent therapy. Effect of Agent Orange ...

  10. Nivolumab shows significant benefit for Hodgkin’s lymphoma in Mayo Clinic co-led phase I study

    In the phase I study, the researchers gave nivolumab every two weeks to 23 patients with relapsed or refractory Hodgkin's lymphoma who were heavily pretreated.